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Abstract: Glycomimetics are compounds that resemble carbohydrate molecules in their chemical structure 
and/or biological effect. A large variety of compounds can be designed and synthesized to get glycomimetics, 
however, C-glycosyl derivatives represent one of the most frequently studied subgroup. In the present survey 
syntheses of a range of five- and six membered C-glycopyranosyl heterocycles, anhydro-aldimine type com-
pounds, exo-glycals, C-glycosyl styrenes, carbon-sulfur bonded oligosaccharide mimics are described. Some of 
the C-glycopyranosyl azoles, namely 1,2,4-triazoles and imidazoles belong to the most efficient glucose analog 
inhibitors of glycogen phosphorylase known to date. Biological studies revealed the therapeutical potential of 
such inhibitors. Other synthetic derivatives offer versatile possibilities to get further glycomimetics.
Keywords: anhydro-aldimines; C-glycosyl compounds; cross couplings; exo-glycals; glycogen phosphory-
lase; glycomimetics; ICS-29; inhibitors; thiol-ene additions; tosylhydrazones.
Introduction
Carbohydrates (saccharides, glycans) are, in the strictest sense, around us and inside us. These compounds 
make about 2/3 of the yearly renewing biomass; they are among the main ingredients of our everyday meals 
either as digestible and nutritious materials or indigestible dietary fibers indispensable for maintaining our 
health; they are components of each living cell, building blocks of the most important biomolecules, and 
participants of forming complex cell organelles; are present in every living organism as skeletal or feed stuffs; 
play a role in all fundamental biological processes from the fertilization via the formation of tissue structure 
and the development of immune response to the apoptosis; they serve as general signaling molecules to 
present a cell’s nature, age and status in cell- and tissue specific recognition events; they are essential compo-
nents of several, in the clinical practice routinely applied medicines and vaccines; are lead structures for drug 
development; they offer solutions to material science problems, as well as power generation and industrial 
production based on renewable feedstocks [1].
The universal role of carbohydrates and their derivatives in the vast majority of biological phenomena 
has become a scientific commonplace in the recent 2–3 decades [2, 3]. The glycans are present in every cell 
and on the cell surface, and their roles are indispensable in each known life form. A present focus of gly-
coscience is to understand the biological roles of natural glycans and glycoconjugates (glycoproteins and 
glycolipids), to map the corresponding saccharide-protein interactions, to decipher the sugar code, the third 
language of biology and, as an outcome, to apply this knowledge in biomedical fields and drug design [4, 5].
Article note: A collection of invited papers based on presentations at the 29th International Carbohydrate Symposium (ICS-29), 
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From the above considerations several goals and tasks can be deduced for the synthetic carbohydrate 
chemistry. One of these is the quest of powerful methods needed to assemble saccharides of limited avail-
ability from natural sources. Due to the complexity of such molecules and the difficulties of chemical syn-
thesis (originating e.g. from the necessity of complicated protecting group strategies [6], from the changing 
ring size, the stereoselective formation of the glycosidic bond [7]), the preparation of glycosides still rep-
resents a serious challenge [8, 9]. A further obstacle of biological studies and applications is represented 
by the sensitivity of the glycosidic bond (Fig. 1a) towards acidic and enzymatic hydrolysis. The unfavorable 
 pharmacokinetic properties also pull back the utility of natural glycans as drugs.
Another task for carbohydrate chemistry is to eliminate the drawbacks connected to the structural pecu-
liarities and synthetic difficulties of glycosides by providing glycomimetics, i.e. compounds resembling the 
structure and/or the biological properties of natural glycans [10]. Some carbohydrate-based glycomimetics 
are exemplified in Fig. 1b, while Fig. 1c illustrates more complex glycomimetic molecules. Such compounds 
may have the advantage of simpler syntheses, resistance toward hydrolysis and metabolic processes, can 
offer a wide range of derivatization possibilities, and can, therefore, be utilized as glycobiological tools and 
leads in drug design.
An outstanding group of glycomimetics modulates, most frequently inhibits the action of glycoenzymes, 
such as glycosyl transferases and glycoside hydrolases. Glycomimetic compounds and glycoenzyme inhibi-
tors are already in use in the clinical practice in several indications, e.g. against blood coagulation, osteoar-
thritis, epilepsy, Gaucher and Niemann-Pick diseases, influenza, diabetes [11]. A most recent breakthrough 
is the introduction of gliflozins for the treatment of type 2 diabetes mellitus. These compounds of C-glycosyl 
arene type structures are inhibitors of renal sodium-dependent glucose cotransporter 2 (SGLT2), thereby 
 eliciting benign glycosuria to diminish blood sugar levels [12–14].
In our work we are dealing with the design and synthesis of glycoenzyme inhibitors (of which those of 
glycogen phosphorylase will be highlighted here) as well as the elaboration of new synthetic methodologies 
to obtain C-glycosyl compounds.
Glucose analog inhibitors of glycogen phosphorylase
Glycogen phosphorylase (GP) can be found in the liver, muscles and brain in slightly different isoforms [15]. 
The liver isoform is the rate determining enzyme for the degradation of the storage polysaccharide glyco-
gen, and this isoenzyme has a direct influence on blood sugar levels. Thus, inhibition of liver GP may result 
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Fig. 1: Glycomimetics. (a) The glycosidic bond in a natural glycan; (b) Some types of glycomimetics; (c) Examples for the 
replacement of the glycosidic oxygen by multiple atomic linkers.
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in a decrease of serum glucose levels, and this enzyme has become a validated target in the search of new 
 therapeutic possibilities of type 2 diabetes [16–19].
The mode of operation and the structure of GP are well known from biochemical and crystallographic 
studies, and seven binding sites have been identified so far [20]. Among these the catalytic site is the most 
intensively studied by glucose derived inhibitors [12, 21–24]. Besides the antidiabetic potential of glycogen 
phosphorylase inhibitors [19, 25, 26] such compounds have the potential for utilization against cardiac 
arrhythmias and other cardiovascular disorders [27, 28], cardiac and cerebral ischemias [29, 30], and  tumorous 
growths [31–36].
The best glucose analog inhibitors of GP displaying submicromolar inhibition constants (Ki) can be found 
among glucopyranosylidene-spiro-heterocycles, N-acyl-N′-β-d-glucopyranosyl ureas, and C-glucopyranosyl 
heterocycles [13, 23]. Here, the most recent results on the latter type of GPIs are summarized.
Design and syntheses of C-glucopyranosyl azoles as glycogen 
phosphorylase inhibitors
Among the first low micromolar GPIs were the N-acetyl-β-d-glucopyranosylamine [37] (Fig. 2a, R = CH3, 
Ki = 32 μM) and its 2-naphthoyl counterpart [38] (Fig. 2a). Later the corresponding ureas (Fig. 2b) and their N-
acyl derivatives (Fig. 2c) were also synthesized and the N-(β-d-glucopyranosyl)-N′-(2-naphthoyl) urea (Fig. 2c) 
was found to be the first submicromolar GPI [23]. These compounds were the basis for bioisosteric replace-
ments [39–42] during which the amide units highlighted in Fig. 2 were substituted by five-membered het-
erocycles leading to a range of C- and N-glucopyranosyl compounds. Compounds were made for each type 
shown in Fig. 2 (heterocycles: pyrrole [43], pyrazole [44], imidazole [43–47], isoxazole [44, 48], thiazole [44], 
1,2,3- [47–52] and 1,2,4-triazoles [53–62], 1,2,4- [63] and 1,3,4-oxadiazoles [51, 64–67], 1,3,4-thiadiazole [65], 
tetrazoles [47, 51, 64]), however, only the syntheses of C-glucopyranosyl 1,2,4-triazoles and imidazoles, essen-
tially unknown before, are described here.
A few trisubstituted C-glucopyranosyl 1,2,4-triazoles were reported in the literature [68, 69], however, 
these proved irreproducible in our laboratory. For the synthesis of the necessary 5-β-d-glucopyranosyl-3-
substituted-1,2,4-triazoles several methods were elaborated (Scheme 1, preparation of the starting com-
pounds was described in the original papers and is not detailed here). Among cyclocondensation routes 
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Fig. 2: Some inhibitors of glycogen phosphorylase [Ki against rabbit muscle GPb (RMGPb)]. N-Acyl-β-d-glucopyranosylamine 
(a), N-substituted-N′-β-d-glucopyranosyl urea (b) and N-acyl-N′-β-d-glucopyranosyl urea (c) type inhibitors as the basic 
compounds for bioisosteric replacements.
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reactions of amidine 1 or acid chloride 2 with amidrazones gave intermediates 4 and 5, respectively, which on 
heating gave the expected 1,2,4-triazoles 8 [54]; transformations of tosylamidrazone 7 by acid chlorides [53], 
or reactions of N-acyl thioamides 10 and 12 with hydrazine [59] also led to 8. A further procedure, represent-
ing a new synthesis for 1,2,4-triazoles in general, was based on the bromination of imidoylhydrazones 3 to 
give the surprisingly stable derivatives 6 which were cyclized to 8 under basic conditions [57]. Finally, ring 
transformations of tetrazole 11 by imidoyl chlorides also gave, via N-benzylated 1,2,4-triazole intermediates, 
the protected triazoles 8 [55] which were debenzoylated under Zemplén conditions to the test compounds 9. 
Taking into account the availability of the necessary carbohydrate precursors and reagents routes 3→6→8 
and 11→8 are the most advantageous. It is worth noting that the transformations of precursors 10–12 facili-
tate the syntheses of all regioisomers of trisubstituted C-glucopyranosyl 1,2,4-triazoles, too [59].
A single representative of C-glycopyranosyl imidazoles, 2-β-d-glucopyranosyl-imidazole [70] was known 
at the outset of our studies. The necessary 2-glycosyl-4(5)-substituted-imidazoles 13a were first prepared by 
the cyclocondensation of amidine 1 and α-bromoketones [44] (Scheme 2). The yields of 13a were improved by 
reactions of imidate 14 with α-aminoketones [43]. The O-perbenzylated 13b were obtained in similar yields 
from imidate 17 while the best results were achieved from amidine 15 [46]. The regioisomeric imidazole 19 
was made from glucose derived α-bromoketone 18 [71]. Standard deprotection protocols led then to the test 
compounds 16 and 20.
A series of fused C-glucopyranosyl imidazole type compounds was also synthesized (Scheme 3). Anhydro-
aldonic acid 21 was condensed with 1,2-diaminobenzene or 2,3-diaminopyridine in the presence of P(OPh)3 to 
give 22 and 24, respectively [45, 72]. Reactions of α-bromoketone 18 with various amino-heterocycles resulted 
in the corresponding annelated derivatives 26, 27, 30, 31, and 34. The O-benzoyl protecting groups were 
removed by the Zemplén protocol to give 23, 25, 28, 29, 32, 33, and 35, respectively. Transformation of 18 with 
O
OBz
BzO
BzO
OBz
C
NH2
NH
O
OBz
BzO
BzO
OBz
C
NH2
N N
C
NH2
R′
O
OBz
BzO
BzO
OBz
COCl
O
OBz
BzO
BzO
OBz
C
O
N
H
N
C
NH2
R′
O H
C N
H
N
NH
R′
OBz
BzO
BzO
OBz
O
C N
H
N
NH
R′
Br
OBz
BzO
BzO
OBz
O
OR
RO
RO
OR
N
NHN
R′
O
OBz
BzO
BzO
OBz
N
N
NHN
O
OBz
BzO
BzO
OBz
C
NH
NHNHTs
O
OBz
BzO
BzO
OBz
N
H
O
R′
S
O
OBz
BzO
BzO
OBz
N
H
S
R′
O
R′
C
NH2
N NH2 R'
C
NH2
N NH2
NBS
NH4OAc,
 AcOH, or
pyridine, ∆
R′ C N Bn,
∆
2. H2, 
    Pd/C
1.
R′COCl
NH2NH2
NH2NH2
4 5 6
∆
∆
∆
Cl
1 (5 steps from D-glucose) 2 (6 steps from D-glucose) (4 steps from
D-glucose)
7 (6 steps from D-glucose) 10 (7 steps from D-glucose)
12 (5 steps from D-glucose)11 (4 steps from D-glucose)
8 R = Bz
9 R = H
NaOMe  MeOH
3
Scheme 1: Key-reactions of the syntheses of C-glucopyranosyl 1,2,4-triazoles.
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2-amino-benzimidazole was only feasible by the derivative benzyl-protected on the ring nitrogen to give 36 
which was first debenzoylated to 37 then debenzylated to 38 [72].
Syntheses of C-glycopyranosyl pyrimidines
The large scale availability of amidine 15 [46, 73] facilitated the first general syntheses of 2-C-β-d-
glucopyranosyl pyrimidines which were practically unknown before (only sporadic mentions could be 
found about similar compounds [74–76]). Although the cyclocondensation of 15 with various 1,3- dicarbonyl 
compounds could be carried out, the removal of the O-benzyl protective groups in the products was prob-
lematic in several cases. Therefore, debenzylation of 15 was performed in the usual way to give 39 (Scheme 4) 
which was then reacted under basic conditions with β-ketoesters, dimethyl malonate, and α,β-unsaturated 
β-chloroketones obtained from β-diketones to furnish C-glucopyranosyl pyrimidines 40, 41, and 42, respec-
tively, in good yields [77].
Since the amidine precursor glycosyl cyanides, such as compounds 43–47 in Scheme 5, are more easily 
accessible in O-peracylated forms, a one-pot procedure was also elaborated to get 2-C-β-d-glycopyranosyl 
pyrimidines from these starting materials [77]. Thus, a glycosyl cyanide 43–47 was treated with NaOMe fol-
lowed by NH4Cl and a β-dicarbonyl reagent in a continuous operation to give pyrimidines 48–54 in 25–94 % 
yields over three steps.
Inhibition of glycogen phosphorylase
The C-β-d-glucopyranosyl heterocycles were assayed against rabbit muscle GPb, the prototype [15] of glyco-
gen phosphorylases. The inhibition data for the azole derivatives are collected in Table 1 together with those 
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of some N-β-d-glucopyranosyl compounds. The structure-activity relationships cannot be analyzed in details 
here, but it can be highlighted that the most efficient inhibitors are imidazole V and 1,2,4-triazole X with 
R = 2-naphthyl substituents (the former is the best known glucose derived GPI). It is noteworthy that both 
types of heterocycles can form H-bonds with the enzyme main chain carbonyl of His377 next to the catalytic 
site as revealed by X-ray crystallography of the enzyme-inhibitor complexes [43, 61, 62]. In each type of the 
investigated compounds the 2-naphthyl-substituted  derivatives proved better inhibitors in comparison to the 
phenyl-substituted ones. This can be attributed to more extensive van der Waals interactions of the former 
in the so-called β-channel of the enzyme [60]. The constitution of the heterocycle linking the glucose moiety 
and the aromatic group as well as the C- or N-glycosidic linkage mode have a decisive effect on the inhibition 
as exemplified by comparisons of V–VII, XI–XII or XIII–XV.
The 2-C-β-d-glucopyranosyl pyrimidines were non-inhibitory at the maximal studied concentration of 
625 μM [77]. This is in sharp contrast with the potency of several N-β-d-glucopyranosyl derivatives of pyrimi-
dine type nucleobases to show low micromolar [78, 79] or even nanomolar inhibition [80]. Why and how the 
C- or N-glycosyl structure of the inhibitors affect the binding still remains to be understood.
Some of the 2-C-β-d-glucopyranosyl pyrimidines had weak inhibition against glycosidase enzymes [77].
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Table 1: Inhibition of rabbit muscle glycogen phosphorylase b (RMGPb) by C- and N-β-d-glucopyranosyl azoles (Ki [μM]).
  n.i.a
n.i.a
     
I        
  n.i.a
n.i.a
     
II        
  400      
III        
  n.i.a     n.i. = no inhibition  
IV        
  0.28
0.031
    37
5.4
    n.i.a
V     VI     VII  
  310
158
    326
23
   
VIII     IX      
  7
0.41
    n.i.a
n.i.a
    151
16
X     XI     XII  
  64
2.4
    10 %a
38
    10 %a
10 %a
XIII     XIV     XV  
  n.i.a     n.i.a     327
XVI     XVII     XVIII  
  625 
(IC50)
    8.6     21
XIX     XX     XXI  
aMeasured at 625 μM the maximal concentration tested.
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Inhibition of RMGPb by compounds modified in the glucose unit
In some series of inhibitors the effects of modifications of the glucose moiety were also studied (Fig. 3). 
The simplest change is to cut off the hydroxymethyl side chain i.e. the synthesis and investigation of xylose 
derivatives. This alteration resulted in inactive compounds among xylopyranosylidene-spiro-heterocycles 
(not shown) [81, 82] and for N-xylosyl-1,2,3-triazoles 56 [82, 83]. In the cases of 1,2,4-triazoles 57 and imi-
dazoles 58, which aglycons gave the best inhibitors with an attached glucose unit, a weakening of three 
orders of magnitude could be observed [82]. Introduction of a double bond into the glucopyranose ring as 
in 59–61, to make the compounds somewhat similar to the glycosyliumion-like transition state of the cata-
lyzed reaction, resulted in inefficient derivatives [84]. However, the exchange of the 2-OH to the isosteric 
NH2 group gave highly active compounds 62–64, nevertheless, these lagged behind the parent glucose 
derivatives by factors of ~22, ~12 and ~6, respectively [85]. These compounds represent the first strongly 
binding GPIs with modified glucose moieties that can be advantageous from the point of view of selectivity 
in applications.
Biological investigations with glucose derived GPIs
Although biological studies with C-glycosyl compounds have not yet been available, other glucose 
derived GPIs had shown promising effects indicating that probably similar efficiencies might be expected 
with the C-glycosyl derivatives, too. In Zucker diabetic rats, administration of glucopyranosylidene- spiro-
thiohydantoin diminished blood sugar levels and also decreased the GPa level in the liver [86]. In addi-
tion, it increased plasma insulin levels and restored the whole body insulin sensitivity in  streptozotocin 
induced diabetic rats [87]. The spiro-thiohydantoin and some N-acyl-N′-β-d-glucopyranosyl ureas 
improved glucose tolerance in mice under normoglycaemic and diabetic conditions [88]. An N-acyl-
N′-β-d-glucopyranosyl urea increased the size of pancreatic Langerhans islets in mice, and improved 
the glucose-induced insulin secretion, thereby, GPIs may be suitable to preserve or even ameliorate 
β-cell function in diabetic states [89]. A single dose of a glucopyranosylidene-spiro-isoxazoline signifi-
cantly lowered the hepatic glucose production (~30 %) which may be relevant for therapeutic applica-
tions [90].
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HO
HO
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HO
HO
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O
HO
HO
OH
O
HO
HO
OH
O
NH2
HO
HO N
OH NN
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HN
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inhibition by the corresponding 
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Fig. 3: Inhibition of RMGPb by compounds with modified glucose units (Ki [μM]).
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Syntheses of other glycomimetics and their precursors
In this section we summarize new synthetic methods for C-glycosyl compounds which can be diversely trans-
formed towards glycomimetics.
Generally applicable reactions were elaborated for the conversion of readily available glycosyl cyanides 
67 to various C-glycosyl imine type compounds (Scheme 6). Under reductive conditions in the presence of 
Raney-Ni, NaH2PO2, and an added acylhydrazine type reagent tosylhydrazones 65 [91–94], acylhydrazones 
66 [95], imidoylhydrazones 68 [57], semicarbazones and carbamoylhydrazones 69 [95] could be prepared 
in good to excellent yields. With hydroxylamine and its derivatives this reaction was not feasible, however, 
transimination of semicarbazones 69 resulted in oximes 70 and 71. Thiosemicarbazones 72 and 73 were pre-
pared similarly from 69 since the direct route from 67 was not possible due to catalyst poisoning by the sulfur 
containing thiosemicarbazide reagents.
Gly C
H
N
H
N S
O
O
CH3
O
CN
TsNHNH2
Gly C
H
N
H
N C
O
BzNHNH2
Raney-Ni, NaH2PO2
AcOH, H2O, pyridine
25–40 °C
R′NHC(=O)NHNH2
Gly C
H
N
H
N C
O
NHR′
R′ = H, Ph
R′C(=NH)NHNH2
Gly C
H
N
H
N C
NH
R′
R′ = NH2, Ph, 2-naphthyl, 2-pyridyl
65 55–99 % 66 58–90 %
68 49–74 % 69 54–89 %
O
AcO
AcO
OAc
OAc
O
RO
RO
OR
OR
O
AcO
AcO
NPhth
OAc
O OAc
OAc
OAc
O
AcO
AcO
OAc
O
AcO
AcO
OAc
O
BzO OBz
BzO
R = Ac, Bz
Gly CH
Gly CH N NH C
O
NH2
HONH2 HCl
abs. CH3CN 
abs. pyridine. BnONH2 HCl.
NH2C(=S)NHNH2 CH3COOH
70 °C
PhNHC(=S)NHNH2
N
OH Gly CH
N
OBn
Gly CH
N
H
N
C
S
NH2 Gly CH
N
H
N
C
S
NHPh
70 65–96 % 71 79–96 %
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67
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Gly
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Scheme 6: Preparation of anhydro-aldimine derivatives.
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Numerous synthetic applications of the above derivatives include oxidative ring closure of 66 and 69 to 
C-glycosyl-1,3,4-oxadiazoles [65–67], transformations of 68 to 1,2,4-triazoles [57], conversion of 73 to 1,3,4-thi-
adiazoles [65]; oximes 70 as nitrile-oxide precursors are starting compounds for 1,3-dipolar cycloadditions 
[96–98].
Next, versatile transformations of tosylhydrazones 65 are presented in details. The well known Bam-
ford-Stevens reaction of tosylhydrazones leads to alkenes in the presence of bases either under thermic 
or photochemical activation. During the transformation the deprotonated hydrazone loses a sulfinate ion 
and nitrogen to give a carbene which, in the absence of any other reaction partner, furnishes an alkene 
by an insertion into the neighboring C–H bond. This reaction was applied for a new, variable synthesis 
of exo-glycals 74 [92, 93, 99] (Table 2). In the presence of a sufficiently large excess of a base the carbene 
insertion into the NH bond of 65 to give 75 becomes subordinate and the exo-glycals 74 can be isolated in 
good yields.
Exo-glycals 74 proved to be excellent substrates for the preparation of glycosylmethyl sulfide type glyco-
mimetics as well as C-S bonded disaccharide mimetics (Scheme 7). To this end, in collaboration with Anikó 
Borbás’ group, photoinitiated thiol-ene addition reactions were applied to give the target compounds 76 in 
mostly very good yields [100–103]. These additions were fully regio- and stereoselective (only the conforma-
tionally more labile d-xylo, 2-deoxy-d-xylo and 2-deoxy-d-arabino derivatives yielded more or less amounts 
of both anomers). Base induced and acid catalyzed additions of thiols to exo-glycals leading to thioglycoside 
type products were discussed in Ref. [103].
The thiol-ene reactions were applied to 1-C-substituted glycals, e.g. 77 [104] (Scheme 8). Additions of 
thiols proceeded with exclusive regio- and stereoselectivity in these cases, as well, furnishing the d-talo con-
figured adducts 78 from 77 of d-lyxo configuration. The yields for compounds 78 diminished depending on 
the 1-C-substituents CONH2 > CO2Me > CN. Since the thiyl radicals are electrophilic, this observation can be 
Table 2: Synthesis of exo-glycals from anhydro-aldose tosylhydrazones 65 [92, 93, 99].
Gly C
H
N
H
N S
O
O
CH3
O
CH2 Gly C
H
N N
Ts
CH2 Glyabs. 1,4-dioxane
reflux
A: NaH (10 equiv.)
Gly
65 74 75
B: K3PO4 (5 equiv.)
or
Gly = CH2          
Isolated yield (%)  74  A: 82   A: 39 + 22 % of 75   A: 72   A: 86 (2 eq NaH)
Gly = CH2          
Isolated yield (%)  74  A: 99 (4 eq NaH) [82]  A: 74   A: 50 (2 eq NaH)  
Gly = CH2          
Isolated yield (%)  74  B: 52 [100]   B: 59 [100]   B: 76 [100]   B: 40 [100]
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well correlated with the Hammett σp values characterizing the electron withdrawing ability of the substitu-
ents as well as the calculated HOMO energy levels of the double bonds. Extension of the thiol-ene additions 
to 1-C-substituted-2-acetoxy-galactals 79 remained unsuccessful.
O
SR′R′SH
+
solvent, hν
2,2-Dimethoxy-
2-phenylacetophenone
(DPAP)
O
AcO
AcO
OAc
OAc
O
AcO
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OAc
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SR′
+
       R′ = e. g. Pr, Ph, Bn, 
                      (AcO)4-β-D-Glcp,                     
                      (AcO)4-β-D-Galp, 
                      (AcO)3-β-D-Xylp, 
(iPrO)2-α-D-Galp-6-yl
O
(RO)n
74 76
76-Glc (74–90 %) 76-Gal (59–87 %) 76-Xyl-β (52–75 %) 76-Xyl-α (3–8 %)
OBzO
BzO
OBz
R′
O
AcO
OAcAcO
R′
+
O
BzO
OBz
SR O
BzO
OBz
SR
OBzO
BzO SR
+ O
OBz
OBz SR
76-2-d-Glc (49–75 %) 76-2-d-Gal (42–76 %)
76-2-d-Xyl-β + 76-2-d-Xyl-α 
70–92 % combined yields β/α 1:0.5–1:2.5
76-2-d-Ara-α + 76-2-d-Ara-β 
46–67 % combined yields β/α 1:5–1:10
Scheme 7: Photoinitiated thiol-ene couplings of exo-glycals.
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Scheme 8: Photoinitiated thiol-ene additions with 1-C-substituted d-galactals.
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In the presence of RXH reagents and bases, tosylhydrazones 65 undergo coupling reactions to produce 
Gly-CH2-X-R type compounds as summarized in Table 3. In such reactions the intramolecular formation of 
exo-glycals 74 is competing with the intermolecular coupling, therefore, 74 can always be isolated from the 
reaction mixtures. Aliphatic alcohols except hexafluoro-isopropanol gave no coupled product 80 (Entries 1 
and 2). With phenols 80 were formed in moderate yields (Entry 3). In the reactions with carboxylic acids the 
yields of 80 increased to give the best results with sugar derived acids (Entries 4–6) [105]. The glycosylmethyl 
sulfides 76 were obtained in moderate and good yields with aliphatic thiols and thiophenols, respectively 
(Entries 7 and 8) [106]. The observed yields and the acidity of the reagents may be correlated: there is no 
Table 3: Couplings of anhydro-aldose tosylhydrazones 65 with hydroxy compounds, carboxylic acids and thiols.
O
(RO)n
H
C N
H
N S
O
O
CH3 O
(RO)n
CH2
O
(RO)n
RXH (2-20 equiv.)
abs. 1,4-dioxane
reflux
+XR
K3PO4 or LiOtBu
D-gluco, D-galacto
R = Ac, Bz
65
76 X = S 
80 X = O
74
(2-10 equiv.)
Entry   R   XH   Product  Isolated 
yield (%)
  pKa (RXH)
1   Aliphatic   OH   80  –  17–14
2   (CF3)2CH-   OH   80  35  9.3
3   Aromatic   OH   80  25–39  10–7
4   Aliphatic   COOH  80  28–58  5–4
5   Aromatic   COOH  80  36–43  4–2.5
6   Sugar   COOH  80  48–66 
7   Aliphatic   SH   76  21–51  11–9
8   Aromatic   SH   76  53–77  7–5
O
(RO)n
CH2
O
(RO)n
+
25–59 %
5–13 %
LiOtBu (1.5 equiv.)
Ar-CH2-Br (6 equiv.)
70 °C, Ar
abs. 1,4-dioxane
 2.5 mol% Pd2(dba)3
20 mol% P(2-furyl)3
Ar
O
(RO)n
H
C N N S
O
O
CH3
Ar
+
2–31 %
O
(RO)n
H
C N
H
N S
O
O
CH3
O
(RO)n
CH2
O
(RO)n
+
30–60 %
4–27 %
LiOtBu (2.2 equiv.)
70 °C, Ar
abs. 1,4-dioxane
Ar
E:Z 1:2 to 1:3
D-gluco, D-galacto
R = Ac, Bz
65
82
74
Ar-Br (6 equiv.)
 2 mol% Pd2(dba)3
 4 mol% CataCXium A
83
74
81
Scheme 9: Syntheses of substituted exo-glycals and ω-(C-glycopyranosyl)-styrenes by Pd-catalyzed cross couplings of anhydro-
aldose tosylhydrazones.
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reaction if the pKa is >11, moderate yields can be achieved in the 11–9 range, while with more acidic com-
pounds the coupling can be rather efficient. It is to be noted, that the two routes applied for the preparation of 
glycosylmethyl sulfides 76 proved complementary: with aliphatic thiols the two-step transformations (thiol 
addition to exo-glycals 74 formed from tosylhydrazones 65), while with thiophenols the direct couplings with 
tosylhydrazones 65 were more efficient in terms of overall yields [106].
Carbenes to be formed from tosylhydrazones are able to coordinate to metal centers e.g. in Pd-complexes. 
Rearrangements of such carbene complexes and subsequent reductive elimination may lead to various prod-
ucts depending on other compounds present in the coordination sphere of the metal. Thus, the reactions 
of 65 with aryl bromides in the presence of Pd2(dba)3 resulted in aryl-substituted exo-glycals 82 [107], while 
with benzyl bromides C-glycopyranosyl styrenes 83 were formed [108] (Scheme 9). In these transformations 
several pathways are open both for the deprotonated tosylhydrazone and the carbene intermediate and, as a 
consequence, the formation of 81 by a nucleophilic substitution of the tosylhydrazone on the benzyl bromide 
as well as that of exo-glycals 74 due to intramolecular insertion can be observed and the by-products can be 
isolated. In the light of these parallel reactions the yields for 82 and 83 are satisfactory and these reactions 
are competitive alternatives of other synthetic methods.
Conclusion
The summarized works demonstrate the versatile transformations based on glycosyl cyanides and other pre-
cursors derived from them to lead to a wealth of glycomimetic compounds. Thus, various C-glycosyl het-
erocycles and other C-glycosyl derivatives like anhydro-aldimine type compounds, exo-glycals, C–S bonded 
oligosaccharide mimetics can be obtained by the elaborated synthetic methods. Some representatives of the 
C-glycosyl heterocycles, notably 1,2,4-triazoles and imidazoles are the most efficient, nanomolar, glucose 
analog inhibitors of glycogen phosphorylase known to date. Biological studies conducted with these and 
other inhibitors demonstrated that beside the expected decrease of blood sugar levels other remarkable 
effects were also induced that may have potential for therapeutic applications.
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